Accordingly, Nikopaschou et al. (2024) recently provided compelling evidence that in e A375 cancer cell lines, blocking ERAP1 function -either through the use of specific inhibitors or via genetic silencing - resulted in a substantial decrease in ROS production. The gene discussed is ERAP1; the disease is cancer.